Allianz SE Raises Holdings in Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA)

Key Points

• Allianz SE increased its stake in Genenta Science S.p.A. by 126.2%, acquiring an additional 130,300 shares to own a total of 233,550 shares, valued at approximately $927,000.
• Algebris UK Ltd also raised its investment in Genenta Science by 122.2%, now owning 100,000 shares worth $368,000 after purchasing 55,000 shares.
• Genenta Science's stock is currently trading at $3.73 with a 52-week range between $2.74 and $7.28.

Allianz SE boosted its position in shares of Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA - Free Report) by 126.2% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 233,550 shares of the company's stock after buying an additional 130,300 shares during the quarter. Allianz SE owned approximately 1.28% of Genenta Science worth $927,000 at the end of the most recent reporting period.

Separately, Citadel Advisors LLC acquired a new position in shares of Genenta Science during the 4th quarter worth about $46,000. 15.13% of the stock is owned by institutional investors and hedge funds.

Genenta Science Price Performance

NASDAQ:GNTA traded up $0.02 during trading hours on Wednesday, hitting $3.80. 806 shares of the stock were exchanged, compared to its average volume of 4,758. The firm's fifty day moving average price is $3.80 and its 200 day moving average price is $3.92. Genenta Science S.p.A. Unsponsored ADR has a 52-week low of $2.74 and a 52-week high of $7.28.

Genenta Science Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.